Ryutaro Matsumura

Chiba, JP 
Chiba, JP 

Overview

Ryutaro Matsumura practices practicing medicine in Chiba, Japan.

Their clinical expertise encompasses Systemic Lupus Erythematosus (SLE), Rheumatoid Lung Disease, Rheumatoid Arthritis (RA), and Arthritis.

They are actively involved in clinical research, co-authoring 26 peer reviewed articles and participating in 4 clinical trials.

Locations

Chiba, Japan
Other Locations
Saitama, Japan
Meguro, 1528621, Japan

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

4 Clinical Trials

A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of LY3471851 (NKTR-358) in Adults With Systemic Lupus Erythematosus
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of LY3471851 (NKTR-358) in Adults With Systemic Lupus Erythematosus
Enrollment Status: Completed
Publish Date: April 23, 2024
Intervention Type: Drug
Study Drug: LY3471851
Study Phase: Phase 2
A Multi-centre Long-term Extension Study to Assess the Safety and Efficacy of GSK3196165 in the Treatment of Rheumatoid Arthritis
A Multi-centre Long-term Extension Study to Assess the Safety and Efficacy of GSK3196165 in the Treatment of Rheumatoid Arthritis
Enrollment Status: Terminated
Publish Date: February 07, 2024
Intervention Type: Drug, Biological
Study Drugs: Otilimab, csDMARD
Study Phase: Phase 3
A 52-week, Phase 3, Multicentre, Randomised, Double Blind, Efficacy and Safety Study, Comparing GSK3196165 With Placebo and With Tofacitinib in Combination With Conventional Synthetic DMARDs, in Participants With Moderately to Severely Active Rheumatoid Arthritis Who Have an Inadequate Response to Conventional Synthetic DMARDs or Biologic DMARDs
A 52-week, Phase 3, Multicentre, Randomised, Double Blind, Efficacy and Safety Study, Comparing GSK3196165 With Placebo and With Tofacitinib in Combination With Conventional Synthetic DMARDs, in Participants With Moderately to Severely Active Rheumatoid Arthritis Who Have an Inadequate Response to Conventional Synthetic DMARDs or Biologic DMARDs
Enrollment Status: Terminated
Publish Date: November 30, 2023
Intervention Type: Drug, Biological
Study Drugs: Otilimab, Tofacitinib, csDMARDs
Study Phase: Phase 3
Low-dose Glucocorticoids Plus Rituximab Versus High-dose Glucocorticoids Plus Rituximab for Remission Induction in ANCA-associated Vasculitis; a Multicentre, Open Label, Randomised Control Trial
Low-dose Glucocorticoids Plus Rituximab Versus High-dose Glucocorticoids Plus Rituximab for Remission Induction in ANCA-associated Vasculitis; a Multicentre, Open Label, Randomised Control Trial
Enrollment Status: Unknown
Publish Date: January 27, 2021
Intervention Type: Drug
Study Drugs: Rituximab, Glucocorticoids
Study Phase: Phase 4
View 3 Less Clinical Trials

26 Total Publications

Efficacy of anifrolumab in systemic lupus erythematosus patients with serological manifestations: A post hoc analysis of the Japan subgroup of the TULIP-2 trial.
Efficacy of anifrolumab in systemic lupus erythematosus patients with serological manifestations: A post hoc analysis of the Japan subgroup of the TULIP-2 trial.
Journal: Modern rheumatology
Published: September 27, 2024

Frequently Asked Questions about Ryutaro Matsumura

Is Ryutaro Matsumura a top-rated expert for Systemic Lupus Erythematosus (SLE)?

MediFind is an objective health platform that identifies experts based on real-world data. Ryutaro Matsumura is classified as an Experienced expert for Systemic Lupus Erythematosus (SLE), meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

Does Ryutaro Matsumura participate in research or clinical trials?

Yes. Ryutaro Matsumura has published 26 articles and abstracts on conditions like Systemic Lupus Erythematosus (SLE). You can view a list of Ryutaro Matsumura's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Matsumura's expertise for a condition
ConditionClose
        View All 11 Experienced Conditions
        Want to save this expert for later?
        Sign Up
        Not sure about your diagnosis?
        Check Your Symptoms
         
         
         
         
        Learn about our expert tiers
        Learn More
        Are you the provider on this profile?
        Claim Profile